文献速递生殖医学

2014至2022年美国跨境辅助生殖技术的使用情况

Cross-border use of assisted reproductive technology in the United States, 2014 to 2022.
PubMed 文献 · Am J Obstet Gynecol · 2026-02-19

该回顾性队列研究基于SART CORS数据,分析2014至2022年2,275,167个辅助生殖技术周期,其中59,246个(2.6%)来自182个国家的非美国居民。非美国居民更常使用ICSI、胚胎植入前遗传学检测、供卵和代孕,且自体和供卵周期的活产率略高。

要点

  • 非美国居民辅助生殖周期占比从2014年2.8%升至2019年3.4%,2020年下降。
  • 中国患者周期数最高(19,718),约为加拿大(6,990)的3倍。
  • 非美国居民更常用ICSI(93% vs 84%)、PGT(68% vs 43%)、供卵(52% vs 9%)和代孕(45% vs 2%)。

核心结论

  • 跨境生殖护理在美国辅助生殖技术周期中占比增长,非美国居民更常使用先进和第三方生殖技术,但结局略优。

研究设计与样本

  • 回顾性队列研究,使用SART CORS数据,纳入2014至2022年2,275,167个辅助生殖技术周期,其中59,246个(2.6%)来自182个国家的非美国居民。

主要发现

  • 非美国居民周期占比从2014年2.8%升至2019年3.4%,2020年下降。
  • 中国患者周期数最高(19,718),加拿大次之(6,990)。
  • 非美国居民更常用ICSI(93% vs 84%)、PGT(68% vs 43%)、供卵(52% vs 9%)和代孕(45% vs 2%)。
  • 自体周期活产率非美国居民48.3% vs 美国居民44.2%,调整RR 1.02(95%CI 1.00-1.04)。
  • 供卵周期活产率非美国居民55.5% vs 美国居民48.4%,调整RR 1.10(95%CI 1.09-1.13)。

临床怎么用

  • 临床医生应了解非美国居民更倾向于使用ICSI、PGT、供卵和代孕等复杂技术。
  • 对于跨境患者,需考虑其治疗偏好和可能的结局差异,提供个体化咨询。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The United States has become a major destination for cross-border reproductive care, yet limited national data exist on international assisted reproductive technology users and their outcomes. OBJECTIVE: To characterize cross-border reproductive care in the United States and compare assisted reproductive technology utilization patterns and outcomes between US and non-US residents. STUDY DESIGN: Retrospective cohort study using data from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System characterizing temporal trends, treatment characteristics, and live birth outcomes among 2,275,167 assisted reproductive technology cycles from 2014 to 2022, including 59,246 (2.6%) cycles from non-US residents representing 182 countries. Outcomes were stratified by oocyte source and plurality (for preterm birth) and analyzed using multivariable log-binomial regression with generalized estimating equations. RESULTS: The number and percentage of assisted reproductive technology cycles among non-US residents rose steadily from 2014 to 2019 (2.8% to 3.4%) before declining in 2020. China accounted for the highest volume of international patients (19,718 cycles), nearly 3-fold higher than the next closest country, Canada (6990 cycles). Compared to US residents, non-US patients were more likely to use intracytoplasmic sperm injection (93% vs 84%), preimplantation genetic testing (68% vs 43%), donor oocytes (52% vs 9%), and gestational carriers (45% vs 2%). Live birth rate was slightly higher among non-US residents for autologous (48.3% vs 44.2%; adjusted risk ratio, 1.02; 95% confidence interval, 1.00-1.04) and donor oocyte cycles (55.5% vs 48.4%; adjusted risk ratio, 1.10; 95% confidence interval, 1.09-1.13). CONCLUSION: Cross-border reproductive care accounts for a growing proportion of assisted reproductive technology cycles in the United States, with non-US residents more frequently using advanced and third-party reproductive technologies. Despite differences in assisted reproductive technology treatments, non-US residents experienced slightly better outcomes. These findings highlight persistent global disparities in assisted reproductive technology access and underscore the United States's role as a key destination for complex fertility care.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Albright NL, Gaskins AJ, Hipp HS, et al. Cross-border use of assisted reproductive technology in the United States, 2014 to 2022. Am J Obstet Gynecol. 2026. PMID: 41722751. doi:10.1016/j.ajog.2026.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。